Assessment of the clinical significance of anti-Do(b)

R. S. Shirey, J. S. Boyd, Karen Eileen King, Patrizio P Caturegli, W. M. Montgomery, Paul Michael Ness

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Anti-Do(b) is an uncommon antibody, and there are few data regarding its clinical importance. In the present case, the patient's transfusion management was based on both in vivo and in vitro assay results. CASE REPORT: A delayed hemolytic transfusion reaction was suspected in a 64- year-old white woman awaiting cardiac surgery when the transfusion of 1 unit of red cells failed to raise her hematocrit. Although direct antiglobulin tests were negative, antibody screening tests on samples drawn 9 days after transfusion were positive, and anti-Do(b) was identified, reacting to a titer of 4. 51Cr in vivo survival studies with incompatible Do(b+) red cells showed poor survival: 83.2 percent at 1 hour, 43 percent at 24 hours, and 29.6 percent at 48 hours and t 1/2 = 19 hours (normal t 1/2 = 25-35 days). A monocyte monolayer assay performed with the same incompatible Do(b+) donor red cells also indicated poor survival: 22 percent and 30 percent reactive monocytes, respectively, with and without the addition of complement (normal, 0-3%). The patient was given 4 Do(b-) red cell units without clinical signs or symptoms of a reaction. CONCLUSIONS: This example of anti-Do(b) was implicated in a delayed hemolytic transfusion reaction. The 51Cr survival studies and monocyte monolayer assay results indicated that the anti-Do(b) was clinically significant, requiring the use of Do(b-) red cells for transfusion.

Original languageEnglish (US)
Pages (from-to)1026-1029
Number of pages4
JournalTransfusion
Volume38
Issue number11-12
StatePublished - Nov 1998

Fingerprint

Monocytes
Survival
Coombs Test
Antibodies
Hematocrit
Thoracic Surgery
Signs and Symptoms
Tissue Donors
Transfusion Reaction
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Shirey, R. S., Boyd, J. S., King, K. E., Caturegli, P. P., Montgomery, W. M., & Ness, P. M. (1998). Assessment of the clinical significance of anti-Do(b). Transfusion, 38(11-12), 1026-1029.

Assessment of the clinical significance of anti-Do(b). / Shirey, R. S.; Boyd, J. S.; King, Karen Eileen; Caturegli, Patrizio P; Montgomery, W. M.; Ness, Paul Michael.

In: Transfusion, Vol. 38, No. 11-12, 11.1998, p. 1026-1029.

Research output: Contribution to journalArticle

Shirey, RS, Boyd, JS, King, KE, Caturegli, PP, Montgomery, WM & Ness, PM 1998, 'Assessment of the clinical significance of anti-Do(b)', Transfusion, vol. 38, no. 11-12, pp. 1026-1029.
Shirey RS, Boyd JS, King KE, Caturegli PP, Montgomery WM, Ness PM. Assessment of the clinical significance of anti-Do(b). Transfusion. 1998 Nov;38(11-12):1026-1029.
Shirey, R. S. ; Boyd, J. S. ; King, Karen Eileen ; Caturegli, Patrizio P ; Montgomery, W. M. ; Ness, Paul Michael. / Assessment of the clinical significance of anti-Do(b). In: Transfusion. 1998 ; Vol. 38, No. 11-12. pp. 1026-1029.
@article{cac1414c660d4aa9b470007dbdda4003,
title = "Assessment of the clinical significance of anti-Do(b)",
abstract = "BACKGROUND: Anti-Do(b) is an uncommon antibody, and there are few data regarding its clinical importance. In the present case, the patient's transfusion management was based on both in vivo and in vitro assay results. CASE REPORT: A delayed hemolytic transfusion reaction was suspected in a 64- year-old white woman awaiting cardiac surgery when the transfusion of 1 unit of red cells failed to raise her hematocrit. Although direct antiglobulin tests were negative, antibody screening tests on samples drawn 9 days after transfusion were positive, and anti-Do(b) was identified, reacting to a titer of 4. 51Cr in vivo survival studies with incompatible Do(b+) red cells showed poor survival: 83.2 percent at 1 hour, 43 percent at 24 hours, and 29.6 percent at 48 hours and t 1/2 = 19 hours (normal t 1/2 = 25-35 days). A monocyte monolayer assay performed with the same incompatible Do(b+) donor red cells also indicated poor survival: 22 percent and 30 percent reactive monocytes, respectively, with and without the addition of complement (normal, 0-3{\%}). The patient was given 4 Do(b-) red cell units without clinical signs or symptoms of a reaction. CONCLUSIONS: This example of anti-Do(b) was implicated in a delayed hemolytic transfusion reaction. The 51Cr survival studies and monocyte monolayer assay results indicated that the anti-Do(b) was clinically significant, requiring the use of Do(b-) red cells for transfusion.",
author = "Shirey, {R. S.} and Boyd, {J. S.} and King, {Karen Eileen} and Caturegli, {Patrizio P} and Montgomery, {W. M.} and Ness, {Paul Michael}",
year = "1998",
month = "11",
language = "English (US)",
volume = "38",
pages = "1026--1029",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11-12",

}

TY - JOUR

T1 - Assessment of the clinical significance of anti-Do(b)

AU - Shirey, R. S.

AU - Boyd, J. S.

AU - King, Karen Eileen

AU - Caturegli, Patrizio P

AU - Montgomery, W. M.

AU - Ness, Paul Michael

PY - 1998/11

Y1 - 1998/11

N2 - BACKGROUND: Anti-Do(b) is an uncommon antibody, and there are few data regarding its clinical importance. In the present case, the patient's transfusion management was based on both in vivo and in vitro assay results. CASE REPORT: A delayed hemolytic transfusion reaction was suspected in a 64- year-old white woman awaiting cardiac surgery when the transfusion of 1 unit of red cells failed to raise her hematocrit. Although direct antiglobulin tests were negative, antibody screening tests on samples drawn 9 days after transfusion were positive, and anti-Do(b) was identified, reacting to a titer of 4. 51Cr in vivo survival studies with incompatible Do(b+) red cells showed poor survival: 83.2 percent at 1 hour, 43 percent at 24 hours, and 29.6 percent at 48 hours and t 1/2 = 19 hours (normal t 1/2 = 25-35 days). A monocyte monolayer assay performed with the same incompatible Do(b+) donor red cells also indicated poor survival: 22 percent and 30 percent reactive monocytes, respectively, with and without the addition of complement (normal, 0-3%). The patient was given 4 Do(b-) red cell units without clinical signs or symptoms of a reaction. CONCLUSIONS: This example of anti-Do(b) was implicated in a delayed hemolytic transfusion reaction. The 51Cr survival studies and monocyte monolayer assay results indicated that the anti-Do(b) was clinically significant, requiring the use of Do(b-) red cells for transfusion.

AB - BACKGROUND: Anti-Do(b) is an uncommon antibody, and there are few data regarding its clinical importance. In the present case, the patient's transfusion management was based on both in vivo and in vitro assay results. CASE REPORT: A delayed hemolytic transfusion reaction was suspected in a 64- year-old white woman awaiting cardiac surgery when the transfusion of 1 unit of red cells failed to raise her hematocrit. Although direct antiglobulin tests were negative, antibody screening tests on samples drawn 9 days after transfusion were positive, and anti-Do(b) was identified, reacting to a titer of 4. 51Cr in vivo survival studies with incompatible Do(b+) red cells showed poor survival: 83.2 percent at 1 hour, 43 percent at 24 hours, and 29.6 percent at 48 hours and t 1/2 = 19 hours (normal t 1/2 = 25-35 days). A monocyte monolayer assay performed with the same incompatible Do(b+) donor red cells also indicated poor survival: 22 percent and 30 percent reactive monocytes, respectively, with and without the addition of complement (normal, 0-3%). The patient was given 4 Do(b-) red cell units without clinical signs or symptoms of a reaction. CONCLUSIONS: This example of anti-Do(b) was implicated in a delayed hemolytic transfusion reaction. The 51Cr survival studies and monocyte monolayer assay results indicated that the anti-Do(b) was clinically significant, requiring the use of Do(b-) red cells for transfusion.

UR - http://www.scopus.com/inward/record.url?scp=0031793037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031793037&partnerID=8YFLogxK

M3 - Article

C2 - 9838932

AN - SCOPUS:0031793037

VL - 38

SP - 1026

EP - 1029

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11-12

ER -